MedTrace Logo

Exoskeleton Gait Training in Guillain-Barré Syndrome: Safety, Feasibility, Usability, and Longitudinal Outcomes

NCT07556809 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-05-08

No results posted yet for this study

Summary

The main objective of the study is to determine if the Atalante X exoskeleton by Wandercraft is a safe, reliable, and usable device for people with Guillain-Barré Syndrome (GBS) who are unable to walk.

The secondary objective is to assess the impact of using this device on the gait and functional recovery of this type of users (GBS).

The users undergo 20 training sessions over 6 weeks. Assessments are carried out at baseline, post-intervention, and at a 4-week follow-up after completing the training sessions. In all assessments, the same outcomes is conducted using the Medical Research Council Outcome, 10-Meter Walk Test, 6-Minute Walking Test, Kansas University Standing Balance Scale, Functional Independence Measure and Level of Assistence. To assess satisfaction, the QUEST 2.0 scale is administered. During this 20 sessions, monitoring is conducted for possible adverse effects that may appear and for the time required for donning and doffing the device.

Conditions

  • Guillain Barré Syndrome

Interventions

DEVICE

Exoskeleton Wandercraft Atalante X, usability and gait rehabilitation

Exoskeleton Wandercraft Atalante X trainning in Guillain Barre syndrome

Sponsors & Collaborators

  • Wandercraft

    collaborator INDUSTRY

  • Institut Guttmann

    lead OTHER

Principal Investigators

  • Eloy E Opisso · Institut Guttmann

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-07
Primary Completion
2025-12-12
Completion
2025-12-12

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07556809 on ClinicalTrials.gov